Back to continue doing my homework. Many folks on the road these past two days have been asking, what's your take on $Novo Nordisk AS(NVO.US)?
1. Checked $Novo Nordisk AS(NVO.US)'s fundamentals, nothing seems wrong.
2. The drop these past two days is due to the Phase 3 clinical trial results for the GLP-1 weight-loss drug CagriSema being inferior to Lilly's (23% vs 25.5% weight loss). Just because it's not as good as a competitor, does it mean this company is doomed?😂
3. When I bought this company's stock, my main focus was on healthcare + AI efficiency improvement.🤔
4. Looking at the current stock price, the dividend yield is around 5%, which is acceptable, so I'll continue holding.
5. This isn't a core holding for me at all, the position is tiny. My core holdings are all in tech stocks.
Not investment advice!
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
